Mind Medicine Archives - Green Market Report

StaffMay 17, 2022
MindMed.jpg?fit=500%2C378&ssl=1

4min1920

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) reported its financial results for the first quarter ending March 31, 2022. At this time, MindMed does not have any revenue to report. The net and comprehensive loss for the quarter was $18.5 million, compared to $13.8 million for the same period in 2021.

The net cash used in operating activities was $12.9 million for the quarter versus $10.0 million for the same period in 2021.  R&D expenses were $10.2 million for the quarter versus $6.8 million for the same period in 2021. MindMed said the increase of $3.4 million was primarily due to $4.4 million of internal expenses related to compensation costs for an additional headcount of $2.0 million and an increase in non-cash expenses of $1.7 million of stock-based compensation expenses.

“The outset of 2022 was marked by significant progress across all aspects of the company that propelled our business forward, as we continued to advance and de-risk our three lead product candidates: MM-120 for the treatment of generalized anxiety disorder, MM-402 for the treatment of core symptoms of autism spectrum disorder, and MM-110 for the management of opioid use disorder,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “We anticipate multiple upcoming catalysts and further growth across our drug development pipeline as well as our enabling technologies. We look forward to building on this momentum and believe we are well-positioned to deliver on the therapeutic potential of psychedelics and other novel targets to transform the treatment of brain health disorders.”

Cash Levels

The company said it has cash of $120 million, down from $133 million for the first quarter in 2021. Despite the large amount of cash on hand, MindMed filed a prospectus for an at-the-market equity offering under which the company may offer and sell its Subordinate Voting Shares or common shares re-designated from the company’s Subordinate Voting Shares  for up to $100 million in aggregate sales proceeds in “at the market” transactions.

The company has a deficit of $156 million and said in it’s last filing, “We expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses in order to discover, develop and market additional potential products.”


Debra BorchardtMarch 28, 2022
shutterstock_1763248556.jpg?fit=960%2C640&ssl=1

4min1870

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED)  reported its financial results for the full year ended December 31, 2021. MindMed has no revenue at this time but did report that the net loss for the year was $92.3 million, compared to $33.7 million for 2020.

MindMed did note that it had cash totaling $133.5 million compared to $80.1 million as of December 31, 2020. The company said this will be enough capital to meet its operating requirements beyond its key development milestones in 2023 and into 2024. That means investors have to look at how the company is spending its money.

G&A Spending

MindMed reported that G&A expenses were $59.1 million for the year versus $14.4 million for 2020. The company attributed part of the increase to $28.9 million in non-cash stock-based compensation expenses of which $21.9 million was related to the modification of stock options and RSUs. The net cash used in operating activities was $45.8 million for the year, compared to $23.6 million for the same period in 2020.

R&D Spending

R&D expenses were $34.8 million for the year compared to $18.6 million for 2020. The company said the jump was primarily due to an increase of $2.7 million in expenses related to its MM-120 clinical research, $2.3 million in expenses related to its MM-110 clinical research, $3.5 million in expenses related to preclinical and other research programs, offset by a $3.5 million decrease of expense in connection with various external R&D collaborations. Internal costs increased $11.1 million primarily related to an increase in non-cash expenses of $6.6 million of stock-based compensation expenses and $2.6 million of amortization of our developed technology.

“2021 was a year of major advancements across all aspects of MindMed, with significant growth in our organization, development programs and research collaborations. We established a regulatory pathway for MM-120 in the treatment of GAD and, with MM-402, launched a program to develop a novel treatment for core symptoms of autism spectrum disorder – both of which represent meaningful leaps forward in the field of psychiatry,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “We expect 2022 to be a transformational year in which we continue to drive substantial growth across our pharmaceutical and digital medicine pipelines. I am incredibly proud of our team’s achievements and I am more confident than ever in our ability to continue advancing our organization and development programs. We are keenly focused on our mission to deliver novel therapies to treat brain health disorders, leading to meaningful improvements in patient outcomes in these major areas of unmet medical need.”

Chopra Deal Is Off

The company said it ultimately did not reach a definitive agreement for potential collaboration with the Chopra Foundation and discontinued the engagement.


Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 9 hours

Canopy Growth Raises Wager on US Expansion, Ups Stake in TerrAscend

@GreenMarketRpt – 9 hours

New York Releases Cannabis Delivery Rules, Pivots on Retail Regulations

@GreenMarketRpt – 10 hours

NYC Cannabis Parties Celebrate Holidaze

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.